Considering these controversial results, along with the wide and complicated involvement of CD40/C40L in physiology and pathophysiology, beyond the already known risks of infection and cancer, we should also be alert to other potential risks when administering patients with medications targeting CD40/C40L. Here, CD40 is linked to cancer.